SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Medical Research Council Oesophageal Cancer Working Group, Surgical resection with and without chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002; 359: 1727-1733.
  • 2
    Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998; 339: 1979-1984.
  • 3
    Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer. 1992; 66: 198-203.
  • 4
    Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003; 39: 1074-1080.
  • 5
    Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656-660.
  • 6
    Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001; 409: 194-198.
  • 7
    Van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004; 25: 426-457.
  • 8
    Ariyasu H, Iwakura H, Yamada G, et al. Efficacy of ghrelin as a therapeutic approach for age related physiological changes. Endocrinology. 2008; 149: 3722-3728.
  • 9
    Akamizu T, Kangawa K. Translational research on the clinical applications of ghrelin. Endocr J. 2006; 53: 585-591.
  • 10
    Adachi S, Takiguchi S, Okada K, et al. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology. 2010; 138: 1312-1320.
  • 11
    Yamamoto K, Takiguchi S, Miyata H, et al. Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery. 2010; 141: 31-38.
  • 12
    Liu YL, Malik NM, Sanger GJ, Andrews PL. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother Pharmacol. 2006; 58: 326-333.
  • 13
    Takeda H, Sadakane C, Hattori T, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology. 2008; 134: 2004-2013.
  • 14
    Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors. 6th ed. New York: John Wiley & Sons; 2002.
  • 15
    Shimakawa T, Naritaka Y, Asaka S, et al. Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer. Anticancer Res. 2008; 28: 2321-2326.
  • 16
    Tanaka Y, Yoshida K, Sanada Y, et al. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2010; 66: 1159-1165.
  • 17
    National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2010. Available from: https://cabig-kc.nci.nih.gov/Vocab/KC/index.php/CTCAE. Accessed January 12, 2012.
  • 18
    Igaki H, Tachimori Y, Kato H. Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Ann Surg. 2004; 239: 483-490.
  • 19
    Japanese Society for Esophageal Diseases. Guidelines for Clinical and Pathologic Studies on Carcinoma in the Esophagus. 9th ed. Tokyo, Japan: Kanehara & Company, Ltd.; 2001.
  • 20
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365-376.
  • 21
    Akamizu T, Shinomiya T, Irako T, et al. Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrinol Metab. 2005; 90: 6-9.
  • 22
    Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010; 151: 3773-3782.
  • 23
    Hiura Y, Takiguchi S, Yamamoto K, et al. Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients [published online ahead of print July 20, 1022]. Int J Clin Oncol. 2011.
  • 24
    Skrtic S, Wallenius K, Gressner AM, Jansson AO. Insulin-like growth factor signaling pathways in rat hepatic stellate cells: importance for deoxyribonucleic acid synthesis and hepatocyte growth factor production. Endocrinology. 1990; 140: 5729-5735.
  • 25
    Kursar JD, Nelson DL, Wainscott DB, Cohen ML, Baez M. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine 2F) from rat stomach fundus. Mol Pharmacol. 1992; 42: 549-557.
  • 26
    Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jannes L. Comparative localization of serotonin 1A, 1C and 2 receptor subtype mRNAs in rat brain. J Comp Neurol. 1995; 351: 357-373.
  • 27
    Nonogaki K, Ohashi-Nozue K, Oka Y. A negative feedback system between brain serotonin systems and plasma active ghrelin levels in mice. Biochem Biophys Res Commun. 2006; 341: 703-707.
  • 28
    Wilder-Smith OH, Borgeat A, Chappuis P, Fathi M, Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer. 1993; 72: 2239-2241.
  • 29
    Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001; 37: 835-842.
  • 30
    Steven G, Daniel C, Anish M, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol. 2011; 29: 1495-1501.
  • 31
    Xiao HB, Cao WX, Yin HR, Lin YZ, Ye SH. Influence of L-methionine-deprived total parenteral nutrition with 5-fluorouracil on gastric cancer and host metabolism. World J Gastroenterol. 2001; 7: 698-701.